Evidence map›Paper›PMID 34692492›Full record

ArticleFrontiers in oncology2021

Genetic Variants of

Lihua Liu, Hongliang Liu, Sheng Luo, Edward F Patz, Carolyn Glass, Li Su, Lijuan Lin, David C Christiani, Qingyi Wei

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Lihua LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hongliang LiuDuke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, United States.
Edward F PatzDuke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Carolyn GlassDuke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Li SuDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States.
Lijuan LinDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States.
David C ChristianiDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Duke University · USDuke Medical Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence supports a role of various damage-associated molecular patterns (DAMPs) in progression of lung cancer, but roles of genetic variants of the DAMPs-related pathway genes in lung cancer survival remain unknown. We investigated associations of 18,588 single-nucleotide polymorphisms (SNPs) in 195 DAMPs-related pathway genes with non-small cell lung cancer (NSCLC) survival in a subset of genotyping data for 1,185 patients from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and validated the findings in another independent subset of genotyping data for 984 patients from Harvard Lung Cancer Susceptibility Study. We performed multivariate Cox proportional hazards regression analysis, followed by expression quantitative trait loci (eQTL) analysis, Kaplan-Meier survival analysis and bioinformatics functional prediction. We identified that two SNPs (i.e.,

Indexed as

damage-associated molecular pattern-related pathwaynon-small cell lung cancersingle-nucleotide polymorphismsurvivalvariant

Identifiers

PMID34692492
PMCPMC8527850
OpenAlexW3204944214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.